全文获取类型
收费全文 | 32435篇 |
免费 | 1849篇 |
国内免费 | 295篇 |
专业分类
耳鼻咽喉 | 302篇 |
儿科学 | 731篇 |
妇产科学 | 647篇 |
基础医学 | 3761篇 |
口腔科学 | 1003篇 |
临床医学 | 2665篇 |
内科学 | 9104篇 |
皮肤病学 | 450篇 |
神经病学 | 3481篇 |
特种医学 | 1202篇 |
外科学 | 4966篇 |
综合类 | 71篇 |
一般理论 | 3篇 |
预防医学 | 1099篇 |
眼科学 | 447篇 |
药学 | 1630篇 |
中国医学 | 31篇 |
肿瘤学 | 2986篇 |
出版年
2023年 | 281篇 |
2022年 | 264篇 |
2021年 | 988篇 |
2020年 | 699篇 |
2019年 | 933篇 |
2018年 | 1033篇 |
2017年 | 815篇 |
2016年 | 929篇 |
2015年 | 1025篇 |
2014年 | 1387篇 |
2013年 | 1810篇 |
2012年 | 2645篇 |
2011年 | 2741篇 |
2010年 | 1499篇 |
2009年 | 1478篇 |
2008年 | 2234篇 |
2007年 | 2294篇 |
2006年 | 2028篇 |
2005年 | 2010篇 |
2004年 | 1956篇 |
2003年 | 1574篇 |
2002年 | 1441篇 |
2001年 | 211篇 |
2000年 | 129篇 |
1999年 | 180篇 |
1998年 | 221篇 |
1997年 | 216篇 |
1996年 | 161篇 |
1995年 | 172篇 |
1994年 | 143篇 |
1993年 | 131篇 |
1992年 | 93篇 |
1991年 | 98篇 |
1990年 | 91篇 |
1989年 | 74篇 |
1988年 | 55篇 |
1987年 | 54篇 |
1986年 | 60篇 |
1985年 | 39篇 |
1984年 | 56篇 |
1983年 | 44篇 |
1982年 | 54篇 |
1981年 | 27篇 |
1980年 | 39篇 |
1979年 | 23篇 |
1978年 | 22篇 |
1977年 | 15篇 |
1976年 | 13篇 |
1967年 | 11篇 |
1966年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Ruscitti Piero Di Cola Ilenia Berardicurti Onorina Conforti Alessandro Iacono Daniela Pantano Ilenia Rozza Gelsomina Rossi Silvia De Stefano Ludovico Balduzzi Silvia Vitale Antonio Caso Francesco Costa Luisa Prete Marcella Navarini Luca Atzeni Fabiola Guggino Giuliana Perosa Federico Cantarini Luca Frediani Bruno Montecucco Carlomaurizio Ciccia Francesco Giacomelli Roberto Cipriani Paola 《Clinical rheumatology》2022,41(11):3597-3597
Clinical Rheumatology - 相似文献
3.
Paul G. Richardson Fredrik Schjesvold Katja Weisel Philippe Moreau Larry D. Anderson Darrell White Paula Rodriguez-Otero Pieter Sonneveld Monika Engelhardt Matthew Jenner Alessandro Corso Jan Dürig Michel Pavic Morten Salomo Meral Beksac Albert Oriol Jindriska Lindsay Anna Marina Liberati Monica Galli Pawel Robak Alessandra Larocca Munci Yagci Filiz Vural Abraham S. Kanate Ruiyun Jiang Lara Grote Teresa Peluso Meletios Dimopoulos 《European journal of haematology》2022,108(1):73-83
4.
5.
Alessandro Mandurino-Mirizzi Vilma Kajana Stefano Cornara Alberto Somaschini Andrea Demarchi Marco Galazzi Gabriele Crimi Marco Ferlini Rita Camporotondo Massimiliano Gnecchi Maurizio Ferrario Luigi Oltrona-Visconti Gaetano M. De Ferrari 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2021,31(7):2140-2143
BackgroundContrast associated-acute kidney injury (CA-AKI) has been associated with adverse outcomes after ST-segment elevation myocardial infarction (STEMI). However, early markers of CA-AKI are still needed to improve risk stratification. We investigated the association between elevated serum uric acid (eSUA) and CA-AKI in patients with STEMI treated with primary percutaneous coronary intervention (pPCI).Methods and resultsSerum creatinine (Scr) was measured at admission and 24, 48 and 72 h after pPCI. CA-AKI was defined as an increase of 25% (CA-AKI 25%) or 0.5 mg/dl (CA-AKI 0.5) of Scr level above the baseline after 48 h following contrast administration. Multivariable analyses to investigate CA-AKI predictors were performed by binary logistic regression and multivariable backward logistic regression model.In the 3023 patients considered, CA-AKI was more frequent among patients with eSUA as compared with patients with normal SUA levels, considering both CA-AKI definitions (CA-AKI25%: 20.8% vs 16.2%, p < 0.012; CA-AKI 0.5: 10.1% vs 5.8%, p < 0.001). The association between eSUA and CA-AKI was confirmed at multivariable analyses (CA-AKI 25%: odd ratio 1.32, 95% CI 1.03–1.69, p = 0.027; CA-AKI 0.5: odd ratio 1.76, 95% CI 1.11–2.79, p = 0.016).ConclusionElevated serum uric acid is associated with CA-AKI after reperfusion in patients with STEMI treated with pPCI. 相似文献
6.
7.
Saleh A Alqahtani Massimo G Colombo 《World journal of gastrointestinal oncology》2021,13(12):2038-2049
Globally, hepatocellular carcinoma (HCC) is a frequently diagnosed malignancy with rapidly increasing incidence and mortality rates. Unfortunately, many of these patients are diagnosed in the advanced stages when locoregional treatments are not appropriate. Before 2008, no effective drug treatments existed to prolong survival, until the breakthrough multi-tyrosine kinase inhibitor (TKI) sorafenib was developed. It remained the standard treatment option for advanced HCC for 10 years, with a battery of other candidate drugs in clinical trials failing to produce similar efficacy results. In 2018, the REFLECT trial introduced another multi-TKI, lenvatinib, which has non-inferior overall survival compared with sorafenib. Thus, offering patients and their treating physicians two effective treatment options. Recently, immunotherapy-based drugs, such as atezolizumab and bevacizumab, have shown promising results in patients with unresectable HCC. This review summarizes clinical trial and real-world data studies of sorafenib and lenvatinib in patients with unresectable HCC. We offer guidance on the optimal choice between the two treatments and discuss the potential of immunotherapy-based combination; when more data become available, this will likely make the choice between sorafenib and lenvatinib somewhat obsolete. 相似文献
8.
Alessandro Rambaldi Alessandra Iurlo Alessandro M. Vannucchi Bruno Martino Attilio Guarini Marco Ruggeri Nikolas von Bubnoff Marianna De Muro Mary Frances McMullin Stefania Luciani Vincenzo Martinelli Axel Nogai Vittorio Rosti Alessandra Ricco Paolo Bettica Sara Manzoni Silvia Di Tollo 《Blood cancer journal》2021,11(3)
9.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
10.
Andrea Ferrari MD Daniel Orbach MD Michela Casanova MD Max M. van Noesel MD Pablo Berlanga MD Bernadette Brennan MD Nadege Corradini MD Reineke A. Schoot MD Gema L. Ramirez-Villar MD Lisa Lyngsie Hjalgrim MD Rita Alaggio MD Gabriela Guillen Burrieza MD Akmal Safwat MD Alison L. Cameron MD Rick R. van Rijn MD Veronique Minard-Colin MD Ilaria Zanetti BSc Gianni Bisogno MD Julia C. Chisholm MD Johannes H. M. Merks MD 《Cancer》2023,129(16):2542-2552
Background
Limited data exist on the clinical behavior of pediatric non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) with distant metastases at onset, and a clear standard of care has not yet been defined.Methods
This cohort study reports on pediatric adult-type metastatic NRSTS enrolled in two concurrent prospective European studies, i.e., the randomized BERNIE study and the single-arm MTS 2008 study developed by the European paediatric Soft tissue sarcoma Study Group. Treatment programs were originally designed for patients with metastatic rhabdomyosarcoma, i.e., nine courses of multidrug chemotherapy (with or without bevacizumab in the BERNIE study), followed by 12 cycles of maintenance therapy, whereas radiotherapy and/or surgery (on primary tumor and/or metastases) were delayed until after seven courses of chemotherapy had been administered.Results
The study included 61 patients <21 years old treated from July 2008 to December 2016. The lung was the site of metastases in 75% of the cases. All patients received multi-agent chemotherapy, 44% had local therapy to primary tumor, and 18% had treatment of metastases. Median time to progression/relapse was 6 months. A high rate of tumor progression was observed during the initial part of the chemotherapy program. With a median follow-up of 41.5 months (range, 2–111 months), 3-year event-free survival and overall survival were 15.4% (95% confidence interval [CI], 7.6–25.7) and 34.9% (95% CI, 22.7–47.5), respectively. There were no statistically significant differences in outcome depending on the type of treatment administered.Conclusions
The study confirmed the overall poor outcome for patients with metastatic NRSTS, whose treatment remains a challenge.Plain Language Summary
- Pediatric non-rhabdomyosarcoma soft tissue sarcomas form a heterogeneous group of rare tumors.
- Although recent international studies have defined the standard of care for patients with localized disease, limited data are available on the clinical behavior of patients with distant metastases.
- This study on 61 metastatic cases treated on two prospective European protocols confirms that the chances of survival of such patients are often dismal and a standard treatment is still lacking.